

Featuring the work of Dr Michael J. Waring *et al.* from AstraZeneca, Alderley Park, UK and Cancer Research Technology, UK.

Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α - but not β -inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation

Two series of inhibitors of type III phosphatidylinositol-4-kinase are presented that selectively inhibit the α - and the β - isoforms with no significant activity towards related pathway kinases. In a cellular environment, inhibition of the α - but not the β - subtype reduced the concentration of proximal biomarkers, causing inhibition of proliferation in a panel of cancer cell lines.

This paper is the first publication of work arising from a strategic alliance between AstraZeneca and Cancer Research Technology focused on bringing forward novel cancer therapies.

As featured in:



See Michael J. Waring *et al.*, *Chem. Commun.*, 2014, 50, 5388.



www.rsc.org/chemcomm

Registered charity number: 207890

Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α - but not β -inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation†

Cite this: *Chem. Commun.*, 2014, 50, 5388

Received 1st November 2013,
Accepted 12th December 2013

DOI: 10.1039/c3cc48391f


www.rsc.org/chemcomm

Michael J. Waring,^a David M. Andrews,^a Paul F. Faulder,^a Vikki Flemington,^a Jennifer C. McKelvie,^b Sarita Maman,^c Marian Preston,^a Piotr Raubo,^a Graeme R. Robb,^a Karen Roberts,^a Rachel Rowlinson,^a James M. Smith,^c Martin E. Swarbrick,^c Iris Treinies,^b Jon J. G. Winter^a and Robert J. Wood^c

Two series of inhibitors of type III phosphatidylinositol-4-kinase were identified by high throughput screening and optimised to derive probe compounds that independently and selectively inhibit the α - and the β -isoforms with no significant activity towards related kinases in the pathway. In a cellular environment, inhibition of the α - but not the β -subtype led to a reduction in phosphatidylinositol-4-phosphate and phosphatidylinositol-4,5-bisphosphate concentration, causing inhibition of inositol-1-phosphate formation and inhibition of proliferation in a panel of cancer cell lines.

Phosphatidylinositol-4-kinases (PI4Ks) catalyse the phosphorylation of phosphatidylinositol (PI) at the D4 position of the inositol head-group to synthesise phosphatidylinositol-4 phosphate (PI4P). PI4P acts as a binding partner for a wide range of proteins with pleckstrin homology (PH) or related lipid-binding domains and has reported roles in membrane trafficking. PI4P is also an important signalling molecule as a precursor to other phosphoinositides such as phosphatidylinositol-4,5-bisphosphate [PI(4,5)P₂] and phosphatidylinositol-3,4,5-trisphosphate [PI(3,4,5)P₃] (Scheme 1).¹

There are four PI4Ks in mammals, termed type II (PI4KII α and β) and type III (PI4KIII α and β , hereafter referred to as PI4K α and β). Each shows differential sub-cellular distributions resulting in compartmentalised PI4P synthesis. PI4K α is the main isoform responsible for PI4P generation at the plasma membrane and is also localised at the endoplasmic reticulum. PI4K β is mainly associated with the Golgi complex where it functions in



Scheme 1 The PI4K cascade.

the generation of Golgi-derived carriers. In addition to the Golgi apparatus, PI4K β has also been visualised on lysosomes where it functions to maintain lysosomal membrane integrity.²

PI4Ks have been implicated in human disease. There are several reports of increased mRNA expression of the different PI4K isoforms in tumours and tumour cell lines.^{3,4} In addition it has been reported that over expression of the Golgi-associated PI4P-binding protein GOLPH3 results in tumour growth and transformation by activating the mTOR signalling pathway.⁵ The gene encoding GOLPH3 is located in a specific region of chromosome 5p13 frequently amplified in solid tumours. There are also several reports of an important role for the PI4Ks in the replication and secretion of multiple viruses.^{6–8}

Pharmacological manipulation of cellular PI4P levels has been a challenge due to the non-specificity and lack of potency of known PI4K inhibitors such as wortmannin, LY294002 and phenylarsine oxide,⁹ although more recently, reports have emerged describing PI4K inhibitors from several groups.^{6–8} Hence, suitable chemical probes that are more potent and selective towards other enzymes in the pathway, with particular emphasis on the downstream kinases PIP5K and PI3K, were sought. These probes would elucidate the roles of PI4K α and β in the PI signalling pathway and investigate the utility of inhibition of these enzymes in disease modification.




^a AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
E-mail: mike.j.waring@astrazeneca.com; Tel: +44 (0)1625 230942

^b Cancer Research Technology, Wolfson Institute for Biomedical Research, University College London, Gower Street, London WC1E 6BT, UK

^c Cancer Research Technology, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, UK

† Electronic supplementary information (ESI) available: Details of experimental procedures, assay protocols and full data for growth inhibition. CCDC 969955. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c3cc48391f





Table 1 Optimisation of PI4K β inhibitor probes

Compound	Structure	PI4K α pIC ₅₀	PI4K β pIC ₅₀	PI3K α pIC ₅₀	PIP5K γ pIC ₅₀
1		8.0	8.3	8.5	6.2
2		5.3	7.2	6.1	6.2
3		5.1	7.8	4.7	<4.0

A set of roughly 100 000 compounds enriched in substructures likely to bind to lipid kinases was selected from the AstraZeneca compound collection and screened against recombinant PI4K β . Active compounds from this screen were selected for follow-up IC₅₀ determination against PI4K α and β . This process revealed acylaminothiazole **1** (Table 1), which was a potent inhibitor of both PI4K α and β (pIC₅₀ 8.0 and 8.3 respectively) but was more active against PI3K α (pIC₅₀ 8.5) and had some residual activity against PIP5K γ (pIC₅₀ 6.2).¹⁰ A series of analogues based on this lead revealed that PI4K α , PI3K and PIP5K activities could all be diminished significantly by changing the position of the nitrogen in the central pyridine ring albeit with a 1.1 log drop in PI4K β potency (illustrated by **2**). Library synthesis varying the thiazole amide showed that both potency and selectivity could be optimised by modifications in this region. As part of this exercise, **3** was revealed as a potent (pIC₅₀ 7.8) inhibitor of PI4K β with good lipid kinase selectivity (pIC₅₀ 5.1, 4.7 and <4.0 vs. PI4K α , PI3K α and PIP5K γ respectively).

The same high throughput screen described above also identified **4** (Table 2), which was appealing as a starting point for a PI4K α probe as it exhibited greater potency for PI4K α (pIC₅₀ 7.0) than PI4K β (pIC₅₀ 6.4). Hence, structural modifications were explored with the aim of improving PI4K α potency and selectivity. Truncation of the ethoxy-substituent of **4** revealed a quite exquisite structure

Table 2 Optimisation of PI4K α inhibitor probes

Compound	Structure	PI4K α pIC ₅₀	PI4K β pIC ₅₀	PI3K α pIC ₅₀	PIP5K γ pIC ₅₀
4		7.0	6.4	5.8	<4.0
5		5.8	6.2	5.8	4.5
6		6.4	6.5	5.6	<4.0
7		8.2	5.9	5.2	<4.0

activity relationship (SAR). Removal of the substituent as in **5** showed a loss of potency and selectivity. This lack of selectivity is perhaps unsurprising since this core motif is preceded to give rise to potent PI3K inhibitors.¹¹

With the substituent removed, other replacements for the 3-pyridyl ring were investigated. Replacement with *N*-methylpyridone **6** led to an increase in potency (for both PI4K α and β) without increasing PI3K activity. Introduction of an *N*-substituent on the pyridone showed that marked gains in potency and selectivity could be achieved once the substituent reached a certain size. Most notably, a significant increase in PI4K α potency was achieved with the *N*-cyclopropylmethyl derivative **7**, which was a potent (pIC₅₀ 8.2) inhibitor of PI4K α with only weak activity against PI4K β , PI3K α or PIP5K γ (pIC₅₀s 5.9, 5.2 and <4.0 respectively).

The observed SAR was rationalised using protein structures of PI3K (pdb code 2CHZ), PI4K α (model based on 4AOF) and PI4K β (model based on 2CHZ). Unselective **1** can dock reasonably into all three models (Fig. 1a and b). In addition to the hinge interaction, the crucial interaction for this compound is between the anionic nitrogen of the sulfonamide (pK_a = 5.6) and the nearby Lys833 residue (PI3K γ). The equivalent Lys is also present in both PI4K isoforms but is far less accessible in the α -isoform. On altering the pyridine substitution pattern as in **2**, this nitrogen is no longer charged, the preferred ligand conformation is altered and the interaction with Lys is lost. In PI4K β , a new interaction is formed between the oxygen of the sulfonamide and the Lys (Fig. 1d) but this cannot be accommodated in PI3K γ , hence the greater selectivity of **2**.

The β -selective **3** docks well into PI4K β (Fig. 1d) but not PI4K α under the same protocol. Comparison with the less selective **2** (Fig. 1c) shows that the acylpiperidine group of **3** would clash with the protein




Fig. 1 Protein homology models with ligands (highlighted with green carbons) bound. Protein Van der Waals surface is shown in yellow; positive directional interactions, including hydrogen-bonds are shown as dotted lines.

in the α -isoform while the same group fits well and makes an additional interaction with a nearby Lys residue in the β -isoform. This is likely due to the Pro residue adjacent to the hinge in PI4K α : the restricted geometry constrains the protein conformation and thus blocks this part of the binding pocket. The equivalent residue in PI4K β (Val) imposes no such restrictions. Even for **2**, the α -isoform scores the pose less well, fitting with the β -bias of the whole series.

The α -selective **7** docks well in the PI4K α model (Fig. 1e) but fails to dock into PI4K β . The similar, but less-selective compound **5** docks well in the β -isoform (Fig. 1f) showing that the pocket in PI4K β is not large enough to accommodate the cyclopropylmethyl group; this group fits well in PI4K α . Critically, Arg1765 in PI4K α defines the subpocket that accepts the cyclopropylmethyl group and reduces the overall volume of the site and preventing the larger compounds **2** and **3** from binding well.

Compounds **3** and **7** were tested at 1 μ M in the Millipore kinase panel consisting of 259 different kinases.¹² Compound **3** showed no activity against any kinase in the panel, **7** only showed activity against three targets (FGR 98%, ZIPK 72% and STK17A 68%, for full results see ESI†). Critically for subsequent experiments, neither compound showed significant activity against PDGFR β .

In order to assess the cellular activity of **3** and **7**, the effect of the compounds on inositol monophosphate (IP₁) was measured. PI4P is phosphorylated by the PIP5Ks to synthesise PI(4,5)P₂. PI(4,5)P₂ is hydrolysed by phospholipase Cs (PLCs) to generate inositol triphosphate and subsequently IP₁. PLC γ can be activated to hydrolyse PI(4,5)P₂ by stimulation of receptor tyrosine kinases. NIH3T3 cells engineered to overexpress PDGFR β were stimulated with PDGF resulting in a dose-dependent increase in IP₁ concentration. Treatment of the cells with **3** and **7** prior to PDGF stimulation revealed that **7** (PI4K α) inhibited the accumulation of IP₁ (pIC₅₀ 6.3) whereas **3** (PI4K β) did not.

In order to examine a more proximal marker of inhibition, tandem mass spectrometry was used for the direct measurement of PIP, PIP₂ and PIP₃. NIH3T3-PDGFR β cells were treated with **7** and **3** (30 μ M for 2 hours) in serum-free media followed by subsequent stimulation with PDGF for 5 minutes. These studies revealed that the PI4K α inhibitor **7** caused a qualitative reduction in cellular PIP, PIP₂ and PIP₃ levels (Table 3 and ESI†).¹³ The PI4K β inhibitor **3** showed no effect.

Since these mass spectrometric measurements are not isomer specific, effects on PI(4,5)P₂ were determined using a fluorescence-based method consisting of a fusion of the PH domain of PLC δ 1, known to specifically bind PI(4,5)P₂, with red fluorescent protein overexpressed in U2OS cells.¹⁴ Treatment of this system with **3** and **7** at 30 μ M showed that **7** (PI4K α) inhibited the formation of basal PI(4,5)P₂ at the membrane (19% inhibition). The PI4K β inhibitor **3** showed no effect.

Table 3 Effects of **3** and **7** on various endpoints in the PI pathway

Compound	IP ₁ pIC ₅₀	Inhibition at 30 μ M			PI(4,5)P ₂ (basal) (%)
		PIP	PIP ₂	PIP ₃	
3	<4.5	—	—	—	0
7	6.3	+	+	+	19




Fig. 2 Heat map of pGI₅₀ values for **3** and **7** in a panel of 183 cancer cell lines. Colour shows pGI₅₀ from 5.0 (yellow) to 6.1 (red), grey <5.0.

Both **3** and **7** were tested for growth inhibition in a panel of 183 cancer cell lines. PI4K α inhibitor **7** inhibited cell growth with pGI₅₀ values of >5.0 in 91 of the cell lines. In contrast, PI4K β inhibitor **3** showed a pGI₅₀ >5.0 in only 18 lines (Fig. 2 and ESI†).

These studies highlight the value of high quality small molecule inhibitors as probes to interpret complex biological cascades. The exquisite selectivity of the chemical probes allows their pharmacology to be ascribed to their intended targets with a high degree of confidence and should be of further utility in the study of PI4K biology and the PI pathway in general.‡

We would like to acknowledge the contributions of a number of colleagues who contributed to the wider project of which this work was a part. In particular, we acknowledge Sabina Cosulich for initiation and early leadership of the project, Robert Garcia for generation of IP₁ data, the AZ cell panel team for generation of the GI₅₀ data and Nullin Divecha for the provision of the U2OS cells used in the PI(4,5)P₂ assay.

Notes and references

‡ Samples of compounds **3** and **7** are available on request for further biological study.

- 1 T. R. Graham and C. G. Burd, *Trends Cell Biol.*, 2011, **21**, 113.
- 2 S. Sridhar, B. Patel, D. Aphkhasava, F. Macian, L. Santambrogio, D. Shields and A. M. Cuervo, *EMBO J.*, 2013, **32**, 324.
- 3 C. Curtis, S. P. Shah, S. F. Chin, G. Turashvili, O. M. Rueda, M. J. Dunning, D. Speed, A. G. Lynch, S. Samarajiwa, Y. Yuan, S. Gräf, G. Ha, G. Haffari, A. Bashashati, R. Russell, S. McKinney, A. Langerød, A. Green, E. Provenzano, G. Wishart, S. Pinder, P. Watson, F. Markowitz, L. Murphy, I. Ellis, A. Purushotham, A.-L. Børresen-Dale, J. D. Brenton, S. Tavaré, C. Caldas and S. Aparicio, *Nature*, 2012, **486**, 346.
- 4 A. Sanchez-Palencia, M. Gomez-Morales, J. A. Gomez-Capilla, V. Pedraza, L. Boyero, R. Rosell and E. Fàrez-Vidal, *Int. J. Cancer*, 2011, **129**, 355.
- 5 K. L. Scott, O. Kabbarah, M. C. Liang, E. Ivanova, V. Anagnostou, J. Wu, S. Dhakal, M. Wu, S. Chen, T. Feinberg, J. Huang, A. Saci, H. R. Widlund, D. E. Fisher, Y. Xiao, D. L. Rimm, A. Protopopov, K.-K. Wong and L. Chin, *Nature*, 2009, **459**, 1085.
- 6 M. J. LaMarche, J. Borawski, A. Bose, C. Capacci-Daniel, R. Colvin, M. Dennehy, J. Ding, M. Dobler, J. Drumm, L. A. Gaither, J. Gao, X. Jiang, K. Lin, U. McKeever, X. Puyang, P. Raman, S. Thohan, R. Tommasi, K. Wagner, X. Xiong, T. Zabawa, S. Zhu and B. Wiedmann, *Antimicrob. Agents Chemother.*, 2012, **56**, 5149.
- 7 A. Bianco, V. Reghellin, L. Donnici, S. Fenu, R. Alvarez, C. Barhuffa, F. Peri, M. Pagani, S. Abrignani, P. Neddermann and R. De Francesco, *PLoS Pathog.*, 2012, **8**, e1002576.
- 8 A. Leivers, M. Tallant, J. B. Shotwell, S. Dickerson, M. R. Leivers, O. B. McDonald, J. Gobel, K. L. Creech, S. L. Strum, A. Mathis, S. Rogers, C. B. Moore and J. Botyanski, *J. Med. Chem.*, 2013, DOI: 10.1021/jm400781h.
- 9 T. Balla and A. Balla, *Trends Cell Biol.*, 2006, **16**, 351.
- 10 Multiple isoforms of PI3K and PIP5K were screened but the data for PI3K α and PIP5K γ are indicative of wider activity.
- 11 M. M. Stec, K. L. Andrews, S. K. Booker, S. Caenepel, D. J. Freeman, J. Jiang, H. Liao, J. McCarter, E. L. Mullady, T. San Miguel, R. Subramanian, N. Tamayo, L. Wang, K. Yang, L. P. Zalameda, N. Zhang, P. E. Hughes and M. H. Norman, *J. Med. Chem.*, 2011, **54**, 5174.
- 12 www.millipore.com.
- 13 This is contradictory to literature reports that depletion of PI4P does not affect steady state levels of PI(4,5)P₂, see N. Jethwa, N. Fili and B. Larijani, *J. Chem. Biol.*, 2012, **5**, 137 and references therein.
- 14 P. Várnai and T. Balla, *J. Cell Biol.*, 1998, **143**, 501.